ASX ANNOUNCEMENT

LATE LODGEMENT OF APPENDIX 3Y

MELBOURNE (AUSTRALIA) 23 November 2026: Invion Limited (ASX: IVX) ("**Invion**" or the "**Company**"), a clinical-stage life sciences company developing its next-generation photodynamic therapy platform (**NGPDT**) called Photosoft™, advises that on 9 October 2026, Alan Yamashita exercised unlisted options in the Company. The attached Appendix 3Y is being lodged late as the change in the director's relevant interests was not identified and reported within the timeframe required under ASX Listing Rule 3.19A.

The Company has arrangements in place to ensure compliance with ASX Listing Rule 3.19A. In this instance, those arrangements did not operate effectively, as the requirement to lodge an Appendix 3Y following the exercise of options by Alan Yamashita was inadvertently overlooked.

No shares issued upon exercise of the options were sold or otherwise disposed of by the director. The Appendix 3Y relates solely to the issue of shares resulting from the exercise of options and the corresponding change in the director's relevant interests.

The Company and its directors are aware of their obligations under ASX Listing Rules 3.19A and 3.19B. Following identification of the oversight, the Company reviewed the circumstances surrounding the late lodgement and has reinforced its internal compliance procedures to assist in ensuring that future notices required under ASX Listing Rule 3.19A are identified and lodged within the prescribed timeframe.

The Company considers the late lodgement to be the result of an inadvertent failure to identify the reporting obligation arising from the option exercise and confirms that the delay did not arise from any lack of awareness of the Company's or the director's obligations under the ASX Listing Rules.

This announcement was approved for release by Invion's Board of Directors.

***Sign up at Invion's Investor Hub to receive regular updates, provide feedback and participate in discussions**: https://investors.inviongroup.com/*

Investor and Media enquiries:

Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: brendon.lau@inviongroup.com

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, ophthalmic and infectious diseases. Invion holds the global exclusive license to the Photosoft technology for multiple cancer and non-cancer disease indications. Invion is listed on the ASX (ASX: IVX). Find out more at www.Inviongroup.com.

About Next Generation Photodynamic Therapy (NGPDT)

Invion is developing its Photosoft™ platform technology as a novel Next Generation Photodynamic Therapy (NGPDT). NGPDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, NGPDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. NGPDT has also demonstrated potential in ophthalmic applications, as well as broad-spectrum antimicrobial activity across multiple bacteria, fungi and viruses.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**INVION LIMITED**
ABN	**76 094 730 417**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Alan Yamashita
Date of last notice	19 June 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	9 October 2026
No. of securities held prior to change	150,053 Ordinary shares 115,541 Listed Share Options 1,352,497 Unlisted Options, nil exercise price per option, expiring 11/06/2029 317,732 Unlisted Options, exercisable at $0.0860 per option, expiring 11/06/2029
Class	Unlisted Options Fully paid ordinary shares
Number acquired	1,352,497 ordinary shares upon the exercise of 1,352,497 unlisted options

+ See chapter 19 for defined terms.

Number disposed	1,352,497 unlisted options upon exercise and conversion into ordinary shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil (zero priced options)
No. of securities held after change	1,502,550 Ordinary shares 115,541 Listed Share Options 317,732 Unlisted Options, exercisable at $0.0860 per option, expiring 11/06/2029
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Conversion of unlisted options into ordinary shares.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

+ See chapter 19 for defined terms.

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.